DrugPatentWatch Database Preview
CABOMETYX Drug Profile
or, see our see our flat-rate plans
When do Cabometyx patents expire, and when can generic versions of Cabometyx launch?
This drug has one hundred and thirty-two patent family members in twenty-eight countries.
The generic ingredient in CABOMETYX is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.
Summary for CABOMETYX
| International Patents: | 132 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 34 |
| Clinical Trials: | 18 |
| Patent Applications: | 1 |
| DailyMed Link: | CABOMETYX at DailyMed |
Pharmacology for CABOMETYX
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors |
Synonyms for CABOMETYX
| (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[( |
| (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1) |
| (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluor |
| (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1) |
| 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)- mono((2S)-2-hydroxybutanedioate) |
| 1140909-48-3 |
| 2296AH |
| 942407-59-2 |
| AC-27471 |
| AKOS025401945 |
| BMS907351 |
| C28H24FN3O5.C4H6O5 |
| Cabozantinib (S-malate) |
| cabozantinib (S)-malate |
| cabozantinib L-malate |
| Cabozantinib L-Malate Salt |
| Cabozantinib malate |
| Cabozantinib malate (XL184) |
| Cabozantinib S-malate |
| Cabozantinib s-malate (USAN) |
| Cabozantinib s-malate [USAN] |
| Cabozantinib(S-malate) |
| CHEBI:72319 |
| CHEMBL2103868 |
| Cometriq (TN) |
| CS-0201 |
| cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (S) malate salt |
| D10095 |
| DR7ST46X58 |
| HFCFMRYTXDINDK-WNQIDUERSA-N |
| HY-12044 |
| KB-75860 |
| KS-00000LA2 |
| MFCD20923480 |
| MLS006010951 |
| MolPort-035-395-744 |
| N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate |
| N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (2S)-2-Hydroxybutanedioic Acid |
| N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2S)-2-hydroxybutanedioate |
| s4001 |
| SC-91041 |
| SMR004702755 |
| UNII-DR7ST46X58 |
| W-5841 |
| XL-184 |
US Patents and Regulatory Information for CABOMETYX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Non-Orange Book US Patents for CABOMETYX
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,178,532 | c-Met modulators and method of use | ➤ Sign Up |
| 2,014,155,378 | ➤ Sign Up | |
| 9,174,947 | c-Met modulators and methods of use | ➤ Sign Up |
| 9,809,549 | Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'(4-fluorophenyl)cycl- opropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
or, see our see our flat-rate plans
International Patents for CABOMETYX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Africa | 201300458 | ➤ Sign Up |
| European Patent Office | 2213661 | ➤ Sign Up |
| Denmark | 2210607 | ➤ Sign Up |
| Australia | 2004275842 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for CABOMETYX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0140029 00117 | Estonia | ➤ Sign Up | PRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014 |
| 0678 | Netherlands | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326 |
| 90053-4 | Sweden | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326 |
| 2014000091 | Germany | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
